Health Systems Under Pressure: Between Climate Emergencies, Epidemics, and Innovations

Ten days after devastating floods in Nepal, rescuers extracted alive a Chinese operator from a hydroelectric tunnel and a 64-year-old Nepalese woman from her buried home. These rescues, which occurred while more than 5,000 people are still missing, illustrate the fragility of health infrastructures in the face of disasters whose intensity is increasing.

Key points

1. Nepal pays a heavy price for climate disasters: floods and debris flows, caused by the collapse of a glacier on the Chinese border, have killed approximately 1,300 people. Rescue operations are focusing on hydroelectric projects, where hundreds of workers are missing. These infrastructures, vital for energy production, have become death traps in the absence of adequate evacuation plans.

2. Malaria declines in Burkina Faso: the Ministry of Health announced a 37.5% drop in cases over two years, representing 1.4 million fewer cases. Cumulative cases decreased from 3.7 million in 2024 to 2.3 million in 2026. This improvement, attributed to the widespread use of impregnated mosquito nets and better access to treatments, shows that progress is possible even in contexts of security fragility.

3. Senegal accelerates towards universal health coverage: a three-day workshop, opened on September 2 in Dakar, brings together the technical committee responsible for designing an integrated national system for health risk coverage. The objective is to move beyond the current piecemeal approach to offer equitable protection to all citizens, a major challenge in a country where the majority of health expenses remain borne by households.

4. French Guiana faces a chikungunya epidemic: with 1,779 confirmed cases and Cayenne Island in an epidemic phase, the Regional Health Agency has authorized pharmacists to directly administer Ixchiq and Vimkunya vaccines. This proximity measure aims to curb the spread of the mosquito-borne virus, in a context where dengue and Zika also remain active.

5. Alzheimer's research reaches a milestone: the international phase III clinical trial PrevenTRON will test Trontinemab, a monoclonal antibody, in asymptomatic adults at high risk identified by the p-tau217 biomarker. Conducted in Europe, this trial could pave the way for targeted prevention of the disease, whereas current treatments only act at the symptom stage.

Context

These seemingly disparate signals are part of the same reality: global health systems are increasingly strained by exogenous shocks — natural disasters, emerging epidemics, demographic aging — while public resources remain constrained. Health resilience has become a major geopolitical issue, as evidenced by the lessons learned from the Covid-19 pandemic and efforts to strengthen national and regional health architectures.

Key players

Fragile states (Nepal, Burkina Faso, DRC): they must reconcile urgent needs (relief, prevention) and long-term investments (universal health coverage). Their capacity for action is limited by insufficient financial resources and dependence on international aid.
International institutions and donors: World Bank, WHO, Gavi, etc. They condition their funding on structural reforms and measurable results, such as the reduction of malaria cases.
Pharmaceutical laboratories: Provepharm, which develops fluorescent surgical dyes with the support of Sofipaca and Région Sud Investissement, illustrates the innovation dynamic driven by European biotechs. Giants like Roche (developer of Trontinemab) invest massively in biomarkers to target at-risk patients.
National health agencies (ARS Guyane, Ministries of Health): they are on the front line to adapt vaccination and prevention strategies to local realities.

Data and figures

According to institutional data, the price of Brent crude oil stood at 96.02 dollars on September 1, 2026, up 10% compared to the end of August (87.03 dollars for WTI). This surge in energy prices, which also affects natural gas (Henry Hub at 2.90 dollars/mmbtu), has direct consequences on the operating costs of hospitals (electricity, heating, transport of medicines) and on household purchasing power, which might have to choose between healthcare and other expenses. Available data show that gas flows at European entry points (Oberkappel, Tarvisio) remained sustained, but variations in renewable production (hydro, wind) in France indicate increased dependence on imports during peak periods.

Analysis of issues

In the short term (1-6 months), health systems in developing countries risk being overwhelmed by multiple emergencies: climate disasters, chikungunya or cholera epidemics, and pressure on drug supply chains. Rich countries are not spared: medical inflation in Mexico, for example, exceeds general inflation, with an expected increase of 14.8% for private care in 2026, which widens inequalities in access to care.

In the medium term (1-3 years), investments in prevention and universal health coverage could bear fruit, as shown by the decline in malaria in Burkina Faso. However, uncertainties remain: antimicrobial resistance, vaccine misinformation (recalled by Brazilian President Lula during his visit to Barretos Hospital) and the fragility of global supply chains could reverse positive trends.

Forward-looking hypotheses

1. Scenario of increased resilience (probability 40%): if international funding for health is maintained and fragile countries strengthen their epidemiological surveillance systems, progress against malaria and preventable diseases will be consolidated. Indicators to monitor: infant and child mortality rates, vaccination coverage, number of countries reaching WHO targets.

2. Systemic crisis scenario (probability 30%): the multiplication of climate shocks (as in Nepal) and emerging epidemics could overwhelm humanitarian intervention capacities, causing localized collapses of health systems. Indicators: number of people displaced for climate reasons, frequency of epidemics, mortality rate during disasters.

3. Technological breakthrough scenario (probability 30%): trials like PrevenTRON and innovations in digital health could transform prevention, but their dissemination will be uneven, widening the gap between high-income and low-income countries. Indicators: results of phase III trials, costs of biomarkers, adoption of technologies in Southern countries.

Why it matters

Every citizen is concerned by the ability of health systems to absorb shocks: a local epidemic can become a pandemic, a climate disaster can disrupt drug supply chains, and medical inflation directly impacts household budgets. Faced with these challenges, the question is no longer whether a new crisis will occur, but whether we will be able to respond collectively. Today's investment choices will determine our vulnerability tomorrow.